Ribon Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $25M
Overview
A clinical-stage company developing first-in-class small molecule inhibitors of MART enzymes for oncology and inflammation.
OncologyImmunology
Technology Platform
A proprietary platform for discovering and developing selective small molecule inhibitors of mono-ADP-ribosyltransferase (MART) enzymes.
Funding History
1Total raised:$25M
PIPE$25M
Opportunities
Potential to establish a new class of targeted therapy in oncology and immunology with a novel mechanism of action.
Risk Factors
Clinical risk associated with pioneering a novel target class where human biology and therapeutic window are not fully established.
Competitive Landscape
A first-mover in the novel MART inhibitor space, with limited direct competition but broader competition from other targeted oncology and immunology therapies.